Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitravatinib + Pembrolizumab in Recurrent dMMR Endometrial Cancer and Solid Tumors
NCT05419817Phase 2Withdrawn
- Start
- Sep 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of sitravatinib in endometrial cancer (EC) and solid tumor. Primary endpoint: Objective Response Rate at 12 weeks. Planned start Sep 2022; status: withdrawn.
02
Drugs
sitravatinib
03
Conditions
endometrial cancer (EC)solid tumor
Beyond the preview
Go deeper on NCT05419817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05419817.